Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Gray Sheet

Executive Summary

OST continues to develop protocols for cleaning, sterilizing, and assessing the performance of single use devices (SUDs) after reprocessing, the annual report notes. For evaluating SUD cleaning protocols, the office developed a "tenacious soil" that simulates biological debris, and formulated a method of chemically tagging biological soils. OST also has been investigating the effect of repeated resterilization with ethylene oxide on balloons and catheters, as well as testing metallic components of gastrointestinal devices for corrosion. Biopsy forceps are among devices on which OST has performed tests; studies by the office were cited in a recent agency letter denying a Boston Scientific citizen petition to revoke the 510(k) exemption for reprocessed SUD Class I biopsy forceps (1"The Gray Sheet" July 23, 2001, p. 26). Separately, the device center office has submitted to the Association for the Advancement of Medical Instrumentation a proposal for a "compendium of cleaning reusable medical devices for reprocessing," OST notes

You may also be interested in...

General Controls, Inspections Suffice For Reprocessed Class I Forceps - FDA

Process validation compliance and monitoring of manufacturing provide reasonable assurances that reprocessed single-use non-electric biopsy forceps are sterile, FDA argues in denying a Boston Scientific citizen petition.

US FDA Still Seeking Sponsor Cooperation For Oncology Label Updates

Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.

Oncology Drug Safety Is Key Focus In US FDA’s Generic Label Updates

US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts